CHICAGO — A single dose of an investigational chimeric antigen receptor T-cell therapy induced an objective response in nearly 90% of patients with relapsed or refractory multiple myeloma, phase 1 study results showed.
Data from the trial — presented at ASCO Annual Meeting — indicated the agent exhibited a manageable safety profile. Researchers reported few cases of high-grade cytokine release syndrome and no treatment-related neurotoxicity.
GC012F (Gracell Biotechnologies) is an autologous, gene-edited, bispecific CAR-T that targets the B-cell maturation antigen (BCMA) and
